FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376106538> ?p ?o ?g. }

• W4376106538 abstract "PURPOSE Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape of metastatic triple-negative breast cancer (TNBC). Trial results have demonstrated the clinical benefit of these targeted agents in the advanced TNBC setting and have led to their evaluation in the treatment of high-risk, early-stage TNBC and BRCA-mutated breast cancer. We provide a summary of the results that have led to the establishment of the ICI pembrolizumab and the PARP inhibitor olaparib as new standards of care. METHODS Using PubMed, we searched for original articles published in English between 2017 and 2022. Search terms included triple-negative breast cancer, adjuvant, neoadjuvant, immunotherapy, and PARP inhibitors. RESULTS Two targeted therapies have been approved by the US Food and Drug Administration for the treatment of TNBC and BRCA-mutated breast cancers in the high-risk, early-stage setting on the basis of clinical trial results demonstrating improved clinical outcomes. For high-risk, early-stage TNBC, pembrolizumab was approved as neoadjuvant therapy in combination with chemotherapy and as a single agent for continued treatment after surgery; this approval was based on results of the KEYNOTE-522 trial. Olaparib was approved for the adjuvant treatment of patients with high-risk, early-stage human epidermal growth factor receptor type 2 (HER2)–negative breast cancer with germline BRCA1/ 2 mutations who have been previously treated with neoadjuvant or adjuvant chemotherapy on the basis of the OlympiA trial results. CONCLUSION Clinical trial results demonstrate the pronounced clinical benefits of pembrolizumab combined with chemotherapy for high-risk, early-stage TNBC and adjuvant olaparib for high-risk, early-stage HER2-negative BRCA1/ 2-mutated breast cancer." @default.
• W4376106538 created "2023-05-12" @default.
• W4376106538 creator A5022891785 @default.
• W4376106538 creator A5080772475 @default.
• W4376106538 date "2023-05-01" @default.
• W4376106538 modified "2023-10-01" @default.
• W4376106538 title "Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline <i>BRCA1</i>/<i>2</i>-Mutated Breast Cancers in the High-Risk, Early-Stage Setting" @default.
• W4376106538 cites W1864994387 @default.
• W4376106538 cites W1961026612 @default.
• W4376106538 cites W1981191944 @default.
• W4376106538 cites W1996778928 @default.
• W4376106538 cites W2002962154 @default.
• W4376106538 cites W2025412572 @default.
• W4376106538 cites W2032323336 @default.
• W4376106538 cites W2086064725 @default.
• W4376106538 cites W2096745115 @default.
• W4376106538 cites W2100413206 @default.
• W4376106538 cites W2116522870 @default.
• W4376106538 cites W2134539328 @default.
• W4376106538 cites W2135088554 @default.
• W4376106538 cites W2138733479 @default.
• W4376106538 cites W2143305439 @default.
• W4376106538 cites W2146384083 @default.
• W4376106538 cites W2158742893 @default.
• W4376106538 cites W2159427817 @default.
• W4376106538 cites W2161977537 @default.
• W4376106538 cites W2214665719 @default.
• W4376106538 cites W2402636472 @default.
• W4376106538 cites W2409054761 @default.
• W4376106538 cites W2539944286 @default.
• W4376106538 cites W2618058692 @default.
• W4376106538 cites W2621271973 @default.
• W4376106538 cites W2627871710 @default.
• W4376106538 cites W2788106879 @default.
• W4376106538 cites W2791483720 @default.
• W4376106538 cites W2885684012 @default.
• W4376106538 cites W2886477543 @default.
• W4376106538 cites W2902218997 @default.
• W4376106538 cites W2904991649 @default.
• W4376106538 cites W2909799373 @default.
• W4376106538 cites W2953287793 @default.
• W4376106538 cites W2970401899 @default.
• W4376106538 cites W3000078203 @default.
• W4376106538 cites W3005738019 @default.
• W4376106538 cites W3005882254 @default.
• W4376106538 cites W3006930853 @default.
• W4376106538 cites W3014160477 @default.
• W4376106538 cites W3092280067 @default.
• W4376106538 cites W3109853980 @default.
• W4376106538 cites W3124119591 @default.
• W4376106538 cites W3126466062 @default.
• W4376106538 cites W3126817559 @default.
• W4376106538 cites W3135041256 @default.
• W4376106538 cites W3165576985 @default.
• W4376106538 cites W3173705400 @default.
• W4376106538 cites W3183205402 @default.
• W4376106538 cites W3185612921 @default.
• W4376106538 cites W3206496593 @default.
• W4376106538 cites W3208558332 @default.
• W4376106538 cites W4206349107 @default.
• W4376106538 cites W4212865994 @default.
• W4376106538 cites W4223904426 @default.
• W4376106538 cites W4225822825 @default.
• W4376106538 cites W4226348827 @default.
• W4376106538 cites W4229079181 @default.
• W4376106538 cites W4281640394 @default.
• W4376106538 cites W4283263207 @default.
• W4376106538 cites W4284895928 @default.
• W4376106538 cites W4285098856 @default.
• W4376106538 cites W4285992810 @default.
• W4376106538 cites W4304084160 @default.
• W4376106538 cites W4311018441 @default.
• W4376106538 cites W4315754639 @default.
• W4376106538 doi "https://doi.org/10.1200/po.22.00446" @default.
• W4376106538 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37163718" @default.
• W4376106538 hasPublicationYear "2023" @default.
• W4376106538 type Work @default.
• W4376106538 citedByCount "0" @default.
• W4376106538 crossrefType "journal-article" @default.
• W4376106538 hasAuthorship W4376106538A5022891785 @default.
• W4376106538 hasAuthorship W4376106538A5080772475 @default.
• W4376106538 hasConcept C104317684 @default.
• W4376106538 hasConcept C121608353 @default.
• W4376106538 hasConcept C126322002 @default.
• W4376106538 hasConcept C143998085 @default.
• W4376106538 hasConcept C182979987 @default.
• W4376106538 hasConcept C2776694085 @default.
• W4376106538 hasConcept C2777701055 @default.
• W4376106538 hasConcept C2779138821 @default.
• W4376106538 hasConcept C2779962180 @default.
• W4376106538 hasConcept C2780057760 @default.
• W4376106538 hasConcept C2780110267 @default.
• W4376106538 hasConcept C2780194787 @default.
• W4376106538 hasConcept C530470458 @default.
• W4376106538 hasConcept C535046627 @default.
• W4376106538 hasConcept C55493867 @default.
• W4376106538 hasConcept C71924100 @default.
• W4376106538 hasConcept C82381507 @default.
• W4376106538 hasConcept C86803240 @default.
• W4376106538 hasConceptScore W4376106538C104317684 @default.

• next